Meeting
2023 ASCO Annual Meeting
SUNMO: A phase III trial evaluating the efficacy and safety of mosunetuzumab in combination with polatuzumab vedotin vs rituximab plus gemcitabine and oxaliplatin in patients with relapsed/refractory aggressive B-cell non-Hodgkin lymphoma.
Authors
Jason Westin
MD Anderson Cancer Center, Houston, TX
Jason Westin , Adam J Olszewski , Laura Fogliatto , Won Seog Kim , Ho-Jin Shin , Young-Woo Jeon , Lalita Norasetthada , Astrid Pavlovsky , Eduardo Rego , Hao Wu , Shen Yin , Connie Lee Batlevi , Song Pham , Elicia M. Penuel , Jing Jing , Michael C. Wei , Lihua Elizabeth Budde
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Track
Hematologic Malignancies
Sub Track
Non-Hodgkin Lymphoma
Clinical Trial Registration Number
NCT05171647
Citation
J Clin Oncol 41, 2023 (suppl 16; abstr TPS7586)
DOI
10.1200/JCO.2023.41.16_suppl.TPS7586
Abstract #
TPS7586
Poster Bd #
133a
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Initial safety run-in results of the phase III POLARGO trial: Polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin in patients (pts) with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL).
First Author: Matthew J. Matasar
Poster
2021 ASCO Annual Meeting
A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).
First Author: Mark Hertzberg
Poster
2021 ASCO Annual Meeting
Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.
First Author: Mehdi Hamadani
Poster
2021 ASCO Annual Meeting
Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).
First Author: Catherine Thieblemont